Show simple item record

dc.contributor.authorSharp, Aen_US
dc.contributor.authorWelti, Jen_US
dc.contributor.authorBlagg, Jen_US
dc.contributor.authorde Bono, JSen_US
dc.date.accessioned2017-03-02T11:34:41Z
dc.date.issued2016-09en_US
dc.identifier.citationClinical cancer research : an official journal of the American Association for Cancer Research, 2016, 22 (17), pp. 4280 - 4282en_US
dc.identifier.issn1078-0432en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/464
dc.identifier.eissn1557-3265en_US
dc.identifier.doi10.1158/1078-0432.ccr-16-1137en_US
dc.description.abstractAndrogen receptor (AR) splice variants (SV) have been implicated in the development of metastatic castration-resistant prostate cancer and resistance to AR targeting therapies, including abiraterone and enzalutamide. Agents targeting AR-SV are urgently needed to test this hypothesis and further improve the outcome of patients suffering from this lethal disease. Clin Cancer Res; 22(17); 4280-2. ©2016 AACRSee related article by Yang et al., p. 4466.en_US
dc.formatPrint-Electronicen_US
dc.format.extent4280 - 4282en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_US
dc.subjectAnimalsen_US
dc.subjectHumansen_US
dc.subjectMiceen_US
dc.subjectReceptors, Androgenen_US
dc.subjectAntineoplastic Agentsen_US
dc.subjectAlternative Splicingen_US
dc.subjectMaleen_US
dc.subjectProtein Interaction Domains and Motifsen_US
dc.subjectMolecular Targeted Therapyen_US
dc.subjectAndrogen Receptor Antagonistsen_US
dc.subjectProstatic Neoplasms, Castration-Resistanten_US
dc.titleTargeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.en_US
dc.typeJournal Article
dcterms.dateAccepted2016-05-26en_US
rioxxterms.versionofrecord10.1158/1078-0432.ccr-16-1137en_US
rioxxterms.licenseref.startdate2016-09en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfClinical cancer research : an official journal of the American Association for Cancer Researchen_US
pubs.issue17en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 1
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Translational Therapeutics
pubs.publication-statusPublisheden_US
pubs.volume22en_US
pubs.embargo.termsNot knownen_US
icr.researchteamMedicinal Chemistry 1en_US
icr.researchteamProstate Cancer Targeted Therapy Groupen_US
icr.researchteamTranslational Therapeuticsen_US
dc.contributor.icrauthorDe Bono, Johannen_US
dc.contributor.icrauthorBlagg, Julianen_US
dc.contributor.icrauthorSharp, Adamen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record